Tadalafil 5 mg Once Daily Improves Lower Urinary Tract Symptoms and Erectile Dysfunction: A Systematic Review and Meta-analysis - PubMed (original) (raw)
Review
doi: 10.1111/luts.12144. Epub 2016 Nov 5.
Affiliations
- PMID: 29341503
- DOI: 10.1111/luts.12144
Review
Tadalafil 5 mg Once Daily Improves Lower Urinary Tract Symptoms and Erectile Dysfunction: A Systematic Review and Meta-analysis
Yilin Wang et al. Low Urin Tract Symptoms. 2018 Jan.
Abstract
Objectives: We carried out a systematic review and meta-analysis to assess tadalafil 5 mg once-daily for the treatment of lower urinary tract symptoms (LUTS) and erectile dysfunction (ED).
Methods: A literature review was performed to identify all published randomized double-blind, placebo-controlled trials of tadalafil 5 mg once-daily for the treatment of LUTS and ED. The search included the following databases: MEDLINE, EMBASE, and the Cochrane Controlled Trials Register. The reference lists of the retrieved studies were also investigated.
Results: Thirteen publications involving a total of 3973 patients were used in the analysis, including 13 RCTs that compared tadalafil 5 mg once-daily with placebo. We found that tadalafil 5 mg once-daily was effective in improving LUTS suggestive of BPH and treating ED over 12 weeks in our meta-analysis. Total International Prostate Symptom Score (IPSS) (SMD = - 2.02, 95% CI = - 2.52 to -1.53, P < 0.00001); Benign Prostatic Hyperplasia Impact Index (BPH-II) (SMD = -0.58, 95% CI = -0.84 to -0.33, P < 0.00001); International Index of Erectile Function-erectile function (IIEF) domain (standardized mean difference [SMD] = 5.18, 95% confidence interval [CI] = 4.13-6.23, P < 0.00001) indicated that tadalafil 5 mg once-daily was more effective than the placebo. Safety assessments included discontinuations due to adverse event (odds ratio (OR) = 1.79, 95% CI = 1.12-2.85, P = 0.01) indicated that tadalafil 5 mg once-daily was well tolerated.
Conclusions: This meta-analysis indicates that tadalafil 5 mg once-daily to be an effective treatment for LUTS and ED with a low occurrence of side effects.
Keywords: erectile dysfunction; lower urinary tract symptoms; meta-analysis; randomized controlled trial; tadalafil.
© 2016 John Wiley & Sons Australia, Ltd.
Similar articles
- Efficacy and Safety of a Fixed-Dose Combination Therapy of Tamsulosin and Tadalafil for Patients With Lower Urinary Tract Symptoms and Erectile Dysfunction: Results of a Randomized, Double-Blinded, Active-Controlled Trial.
Kim SW, Park NC, Lee SW, Yang DY, Park JK, Moon DG, Yang SK, Lee SW, Moon KH, Ahn TY, Kim SW, Park K, Min KS, Ryu JK, Son H, Jung J, Hyun JS. Kim SW, et al. J Sex Med. 2017 Aug;14(8):1018-1027. doi: 10.1016/j.jsxm.2017.06.006. J Sex Med. 2017. PMID: 28760246 Clinical Trial. - Tadalafil once daily in the treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in men without erectile dysfunction.
Brock G, Broderick G, Roehrborn CG, Xu L, Wong D, Viktrup L. Brock G, et al. BJU Int. 2013 Nov;112(7):990-7. doi: 10.1111/bju.12251. Epub 2013 Aug 13. BJU Int. 2013. PMID: 23937669 Clinical Trial. - Tadalafil - a therapeutic option in the management of BPH-LUTS.
Carson CC, Rosenberg M, Kissel J, Wong DG. Carson CC, et al. Int J Clin Pract. 2014 Jan;68(1):94-103. doi: 10.1111/ijcp.12305. Int J Clin Pract. 2014. PMID: 24341303 Review.
Cited by
- Medical Advancements in Benign Prostatic Hyperplasia Treatments.
Ganesan V, Agarwal D. Ganesan V, et al. Curr Urol Rep. 2024 May;25(5):93-98. doi: 10.1007/s11934-024-01199-4. Epub 2024 Mar 7. Curr Urol Rep. 2024. PMID: 38448685 Review. - Treatment Algorithm for Management of Benign Prostatic Obstruction: An Overview of Current Techniques.
Hughes T, Harper P, Somani BK. Hughes T, et al. Life (Basel). 2023 Oct 18;13(10):2077. doi: 10.3390/life13102077. Life (Basel). 2023. PMID: 37895457 Free PMC article. Review. - Treating LUTS in Men with Benign Prostatic Obstruction: A Review Article.
Murad L, Bouhadana D, Nguyen DD, Chughtai B, Zorn KC, Bhojani N, Elterman DS. Murad L, et al. Drugs Aging. 2023 Sep;40(9):815-836. doi: 10.1007/s40266-023-01054-0. Epub 2023 Aug 9. Drugs Aging. 2023. PMID: 37556075 Review. - Update on the management of benign prostatic hyperplasia and the role of minimally invasive procedures.
Franco JVA, Tesolin P, Jung JH. Franco JVA, et al. Prostate Int. 2023 Mar;11(1):1-7. doi: 10.1016/j.prnil.2023.01.002. Epub 2023 Jan 10. Prostate Int. 2023. PMID: 36910900 Free PMC article. Review. - Phloretin in Benign Prostate Hyperplasia and Prostate Cancer: A Contemporary Systematic Review.
Yang CH, Ou YC, Lin CC, Lin YS, Tung MC, Yu CC, Lin JT, Wen CY. Yang CH, et al. Life (Basel). 2022 Jul 11;12(7):1029. doi: 10.3390/life12071029. Life (Basel). 2022. PMID: 35888117 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical